Diabetes

December 30, 2017

Vitamin B-based therapy for TIIDM and obesity-associated metabolic deficits: A therapeutic mix (PMFA) encompassing Pyridoxamine (PM) and Folic acid (FA) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 30/December/2017, 11.21 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]
December 30, 2017

Natural product-derived regenerative therapy for reversing diabetes: A pharmaceutical mixture encompassing Luteolin, Apigenin and Loureirin B (LALB) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 30/December/2017, 10.56 pm

Introduction: What they say A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, […]
December 29, 2017

Natural product-based therapy for Metabolic diseases: A pharmaceutical mixture [PMSFN] encompassing Pyridoxamine(PM) and Sulforaphane (SFN) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 29/December/2017, 11.01 pm

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June […]
December 28, 2017

Molecular therapy for TIIDM and Metabolic defects: A pharmaceutical mixture (PMEA) encompassing Pyridoxamin (PM) and Etacrynic acid (EA)  increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 29/December/2017, 12.03 am

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC […]